CAI
Caris Life Sciences, Inc.
Price Chart
Latest Quote
$18.47
+0.61 (+3.42%)
Current Price
| Previous Close | $17.86 |
| Open | $18.25 |
| Day High | $18.52 |
| Day Low | $17.76 |
| Volume | 2,106,386 |
Stock Information
| Shares Outstanding | 282.68M |
| Total Debt | $430.96M |
| Cash Equivalents | $823.46M |
| Revenue | $907.29M |
| Net Income | $-411.42M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $5.22B |
| EPS (TTM) | $-2.76 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $4.69B |
| Sales | $907.29M |
| Income | $-411.42M |
| Book/sh | $2.10 |
| Cash/sh | $2.91 |
| Employees | 2K |
Financial Ratios
| Quick Ratio | 6.35 |
| Current Ratio | 7.05 |
| Debt/Eq | 72.61 |
Returns & Margins
| ROA | 9.31% |
| ROE | 28.35% |
| Gross Margin | 68.92% |
| Operating Margin | 2.44% |
| Profit Margin | 3.75% |
Ownership
| Insider Ownership | 48.51% |
| Institutional Ownership | 56.66% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 50.50 |
| P/S | 5.75 |
| P/B | 8.80 |
Analyst Data
| Recommendation | buy |
| Target Price | $27.83 |
Technical Indicators
| SMA20 | $16.84 |
| SMA50 | $17.75 |
| SMA200 | $23.89 |
| RSI | 61.90 |
| ATR | 1.0796 |
| Shares Float | 103.39M |
| Short Float | 9.31% |
| Short Ratio | 3.41 |
| Rel Volume | 0.98 |
Performance History
| Week | +2.61% |
| Month | +23.46% |
| Quarter | -1.81% |
| 6 Months | -33.08% |
| YTD | -31.54% |
| 10 Years | -34.04% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $18.47 | 2,398,300 |
| 2026-06-17 | $17.86 | 2,349,800 |
| 2026-06-16 | $17.98 | 1,804,600 |
| 2026-06-15 | $18.18 | 1,579,300 |
| 2026-06-12 | $17.97 | 1,961,400 |
| 2026-06-11 | $18.00 | 2,384,800 |
| 2026-06-10 | $17.16 | 2,606,000 |
| 2026-06-09 | $16.96 | 3,534,000 |
| 2026-06-08 | $16.14 | 3,403,000 |
| 2026-06-05 | $16.49 | 2,740,800 |
| 2026-06-04 | $17.28 | 3,197,700 |
| 2026-06-03 | $15.48 | 2,807,800 |
| 2026-06-02 | $16.52 | 2,572,900 |
| 2026-06-01 | $16.45 | 2,611,300 |
| 2026-05-29 | $16.72 | 2,185,800 |
| 2026-05-28 | $16.67 | 2,788,200 |
| 2026-05-27 | $15.38 | 1,869,600 |
| 2026-05-26 | $15.52 | 2,004,100 |
| 2026-05-22 | $15.55 | 1,804,300 |
| 2026-05-21 | $15.94 | 2,456,800 |
| 2026-05-20 | $15.70 | 2,715,800 |
| 2026-05-19 | $14.96 | 2,460,700 |
About Caris Life Sciences, Inc.
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients. The company was founded in 2008 and is headquartered in Irving, Texas.
đ° Latest News
Caris Life Sciences (CAI) Announces $100M Share Repurchase Program
Insider Monkey âĸ 2026-06-17T19:38:58Z
Caris Life Sciences Announces That Itâs Dual Listing on NYSE Texas
NYSE âĸ 2026-06-16T15:26:23Z
Youâve Likely Never Heard of Caris Life Sciences Stock. Billionaire Stanley Druckenmiller Has â and He Likes What He Sees.
Barchart âĸ 2026-05-20T17:34:16Z
Caris Life Sciences Advances Precision Oncology As Shares Trade Below Targets
Simply Wall St. âĸ 2026-05-19T19:06:12Z
Another billionaire dumps mega-cap stock for AI bet
TheStreet âĸ 2026-05-18T02:03:00Z
Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying.
Barrons.com âĸ 2026-05-15T21:59:00Z
Caris Life Sciences Eyes Bigger Oncology Market After IPO as Revenue Jumps 79%
MarketBeat âĸ 2026-05-13T09:06:39Z
Should Carisâs Q1 Revenue Surge and New AI Cancer Tests Require Action From Caris Life Sciences (CAI) Investors?
Simply Wall St. âĸ 2026-05-09T18:13:23Z
Assessing Caris Life Sciences (CAI) Valuation As Shares Trade Below Narrative Fair Value
Simply Wall St. âĸ 2026-05-09T06:13:51Z
Caris (CAI) Q1 2026 Earnings Call Transcript
Motley Fool âĸ 2026-05-07T22:48:53Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $272,865,000 | $233,478,000 | $216,818,000 | $178,463,000 |
| Cost Of Revenue | $272,865,000 | $233,478,000 | $216,818,000 | $178,463,000 |
| Total Revenue | $812,033,000 | $412,260,000 | $306,128,000 | $258,485,000 |
| Operating Revenue | $812,033,000 | $412,260,000 | $306,128,000 | $258,485,000 |
| Expenses | ||||
| Interest Expense | $56,853,000 | $50,025,000 | $31,610,000 | $26,680,000 |
| Total Expenses | $766,920,000 | $669,382,000 | $625,679,000 | $574,241,000 |
| Other Income Expense | $-72,845,000 | $18,135,000 | $-1,512,000 | $20,662,000 |
| Other Non Operating Income Expenses | $-665,000 | $-349,000 | $-1,691,000 | $-92,000 |
| Net Non Operating Interest Income Expense | $-40,356,000 | $-42,903,000 | $-20,352,000 | $-25,733,000 |
| Interest Expense Non Operating | $56,853,000 | $50,025,000 | $31,610,000 | $26,680,000 |
| Operating Expense | $494,055,000 | $435,904,000 | $408,861,000 | $395,778,000 |
| Selling And Marketing Expense | $167,506,000 | $152,602,000 | $142,925,000 | $138,356,000 |
| General And Administrative Expense | $224,965,000 | $169,386,000 | $149,053,000 | $156,154,000 |
| Rent Expense Supplemental | - | $8,385,000 | $9,985,000 | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-68,088,000 | $-281,890,000 | $-341,415,000 | $-320,827,000 |
| Net Interest Income | $-40,356,000 | $-42,903,000 | $-20,352,000 | $-25,733,000 |
| Interest Income | $16,497,000 | $7,122,000 | $11,258,000 | $947,000 |
| Normalized Income | $4,092,000 | $-300,374,000 | $-341,594,000 | $-341,581,000 |
| Net Income From Continuing And Discontinued Operation | $-68,088,000 | $-281,890,000 | $-341,415,000 | $-320,827,000 |
| Total Operating Income As Reported | $45,113,000 | $-257,122,000 | $-319,551,000 | $-315,756,000 |
| Net Income Common Stockholders | $-537,957,000 | $-378,257,000 | $-462,527,000 | $-399,828,000 |
| Net Income | $-68,088,000 | $-281,890,000 | $-341,415,000 | $-320,827,000 |
| Net Income Including Noncontrolling Interests | $-68,088,000 | $-281,890,000 | $-341,415,000 | $-320,827,000 |
| Net Income Continuous Operations | $-68,088,000 | $-281,890,000 | $-341,415,000 | $-320,827,000 |
| Pretax Income | $-68,088,000 | $-281,890,000 | $-341,415,000 | $-320,827,000 |
| Special Income Charges | $-19,895,000 | $0 | $-10,915,000 | $0 |
| Interest Income Non Operating | $16,497,000 | $7,122,000 | $11,258,000 | $947,000 |
| Operating Income | $45,113,000 | $-257,122,000 | $-319,551,000 | $-315,756,000 |
| Gross Profit | $539,168,000 | $178,782,000 | $89,310,000 | $80,022,000 |
| Depreciation Amortization Depletion Income Statement | - | $128,000 | $500,000 | - |
| Depreciation And Amortization In Income Statement | - | $128,000 | $500,000 | - |
| Depreciation Income Statement | - | $128,000 | $500,000 | - |
| Per Share | ||||
| Diluted EPS | $-3.22 | $-1.36 | $-1.82 | $-1.57 |
| Basic EPS | $-3.22 | $-1.36 | $-1.82 | $-1.57 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $83,560,000 | $-201,436,000 | $-260,983,000 | $-266,648,000 |
| Total Unusual Items | $-72,180,000 | $18,484,000 | $179,000 | $20,754,000 |
| Total Unusual Items Excluding Goodwill | $-72,180,000 | $18,484,000 | $179,000 | $20,754,000 |
| Reconciled Depreciation | $22,615,000 | $48,913,000 | $49,001,000 | $48,253,000 |
| EBITDA (Bullshit earnings) | $11,380,000 | $-182,952,000 | $-260,804,000 | $-245,894,000 |
| EBIT | $-11,235,000 | $-231,865,000 | $-309,805,000 | $-294,147,000 |
| Diluted Average Shares | $167,205,616 | $277,932,779 | $254,788,878 | $254,788,878 |
| Basic Average Shares | $167,205,616 | $277,932,779 | $254,788,878 | $254,788,878 |
| Diluted NI Availto Com Stockholders | $-537,957,000 | $-378,257,000 | $-462,527,000 | $-399,828,000 |
| Otherunder Preferred Stock Dividend | $85,433,000 | $96,367,000 | $121,112,000 | $79,001,000 |
| Preferred Stock Dividends | $384,436,000 | $384,436,000 | $121,112,000 | $79,001,000 |
| Tax Provision | $0 | $0 | $0 | $0 |
| Other Special Charges | $19,895,000 | - | $10,915,000 | - |
| Gain On Sale Of Security | $-52,285,000 | $18,484,000 | $11,094,000 | $20,754,000 |
| Research And Development | $101,584,000 | $113,916,000 | $116,883,000 | $101,268,000 |
| Selling General And Administration | $392,471,000 | $321,988,000 | $291,978,000 | $294,510,000 |
| Other Gand A | $224,965,000 | $169,386,000 | $149,053,000 | $156,154,000 |
| Rent And Landing Fees | - | $6,738,000 | $8,037,000 | - |
| Salaries And Wages | - | $12,749,000 | $10,383,000 | - |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $557,963,000 | $-2,518,182,000 | $-2,164,294,000 | $-1,721,457,000 |
| Total Assets | $1,125,663,000 | $343,734,000 | $412,900,000 | $717,422,000 |
| Total Non Current Assets | $127,863,000 | $128,005,000 | $170,288,000 | $201,378,000 |
| Other Non Current Assets | $45,349,000 | $40,844,000 | $3,430,000 | $43,985,000 |
| Goodwill And Other Intangible Assets | $19,344,000 | $19,344,000 | $19,344,000 | $19,344,000 |
| Current Assets | $997,800,000 | $215,729,000 | $242,612,000 | $516,044,000 |
| Other Current Assets | $2,355,000 | $6,708,000 | $1,358,000 | $1,932,000 |
| Restricted Cash | $1,525,000 | $1,492,000 | $3,605,000 | $3,948,000 |
| Prepaid Assets | $19,586,000 | $13,562,000 | $11,766,000 | $13,357,000 |
| Inventory | $63,625,000 | $39,572,000 | $48,998,000 | $46,956,000 |
| Receivables | $112,140,000 | $88,244,000 | $55,299,000 | $40,227,000 |
| Accounts Receivable | $112,140,000 | $88,244,000 | $48,699,000 | $40,227,000 |
| Cash Cash Equivalents And Short Term Investments | $798,569,000 | $66,151,000 | $121,586,000 | $409,624,000 |
| Cash And Cash Equivalents | $796,274,000 | $63,950,000 | $56,402,000 | $107,191,000 |
| Other Receivables | - | $4,600,000 | $6,600,000 | - |
| Debt | ||||
| Total Debt | $427,686,000 | $424,259,000 | $217,107,000 | $270,872,000 |
| Long Term Debt And Capital Lease Obligation | $421,158,000 | $358,089,000 | $210,520,000 | $213,779,000 |
| Long Term Debt | $378,450,000 | $319,195,000 | $166,106,000 | $169,574,000 |
| Current Debt And Capital Lease Obligation | $6,528,000 | $66,170,000 | $6,587,000 | $57,093,000 |
| Net Debt | - | $315,245,000 | $109,704,000 | $115,172,000 |
| Current Debt | - | $60,000,000 | $167,000 | $52,789,000 |
| Other Current Borrowings | - | $60,000,000 | $167,000 | $52,789,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $548,356,000 | $2,842,572,000 | $2,557,850,000 | $2,419,535,000 |
| Total Non Current Liabilities Net Minority Interest | $421,211,000 | $2,677,149,000 | $2,462,712,000 | $2,282,629,000 |
| Derivative Product Liabilities | $53,000 | $97,409,000 | $126,908,000 | $114,678,000 |
| Current Liabilities | $127,145,000 | $165,423,000 | $95,138,000 | $136,906,000 |
| Other Current Liabilities | $327,000 | $4,957,000 | $5,471,000 | $4,957,000 |
| Current Deferred Liabilities | $24,492,000 | $7,470,000 | $5,676,000 | $1,434,000 |
| Payables And Accrued Expenses | $64,311,000 | $61,090,000 | $60,580,000 | $55,729,000 |
| Payables | $39,206,000 | $27,791,000 | $26,680,000 | $27,269,000 |
| Accounts Payable | $39,206,000 | $27,791,000 | $26,680,000 | $27,269,000 |
| Interest Payable | - | $0 | $6,332,000 | $133,000 |
| Equity | ||||
| Common Stock Equity | $577,307,000 | $-2,498,838,000 | $-2,144,950,000 | $-1,702,113,000 |
| Total Equity Gross Minority Interest | $577,307,000 | $-2,498,838,000 | $-2,144,950,000 | $-1,702,113,000 |
| Stockholders Equity | $577,307,000 | $-2,498,838,000 | $-2,144,950,000 | $-1,702,113,000 |
| Gains Losses Not Affecting Retained Earnings | $936,000 | $210,000 | $218,000 | $1,698,000 |
| Other Equity Adjustments | $936,000 | $210,000 | $218,000 | $1,698,000 |
| Retained Earnings | $-2,548,736,000 | $-2,472,300,000 | $-2,119,175,000 | $-1,678,650,000 |
| Preferred Securities Outside Stock Equity | $0 | $2,221,651,000 | $2,125,284,000 | $1,954,172,000 |
| Other Equity Interest | - | $-26,456,000 | $-25,701,000 | $-24,969,000 |
| Other | ||||
| Treasury Shares Number | $1,611,713 | - | - | - |
| Ordinary Shares Number | $282,526,097 | $277,932,779 | $277,932,779 | $277,932,779 |
| Share Issued | $284,137,810 | $277,932,779 | $277,932,779 | $277,932,779 |
| Tangible Book Value | $557,963,000 | $-2,518,182,000 | $-2,164,294,000 | $-1,721,457,000 |
| Invested Capital | $955,757,000 | $-2,119,643,000 | $-1,978,844,000 | $-1,479,750,000 |
| Working Capital | $870,655,000 | $50,306,000 | $147,474,000 | $379,138,000 |
| Capital Lease Obligations | $49,236,000 | $45,064,000 | $51,001,000 | $48,509,000 |
| Total Capitalization | $955,757,000 | $-2,179,643,000 | $-1,978,844,000 | $-1,532,539,000 |
| Treasury Stock | $16,896,000 | $330,000 | $330,000 | $330,000 |
| Additional Paid In Capital | $3,141,720,000 | $0 | $0 | $0 |
| Capital Stock | $283,000 | $38,000 | $38,000 | $138,000 |
| Common Stock | $283,000 | $38,000 | $38,000 | $138,000 |
| Long Term Capital Lease Obligation | $42,708,000 | $38,894,000 | $44,414,000 | $44,205,000 |
| Current Deferred Revenue | $24,492,000 | $7,470,000 | $5,676,000 | $1,434,000 |
| Current Capital Lease Obligation | $6,528,000 | $6,170,000 | $6,587,000 | $4,304,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $31,487,000 | $25,736,000 | $16,824,000 | $17,693,000 |
| Current Accrued Expenses | $25,105,000 | $33,299,000 | $33,900,000 | $28,460,000 |
| Goodwill | $19,344,000 | $19,344,000 | $19,344,000 | $19,344,000 |
| Net PPE | $63,170,000 | $67,817,000 | $147,514,000 | $138,049,000 |
| Accumulated Depreciation | $-240,980,000 | $-228,609,000 | $-184,136,000 | $-135,102,000 |
| Gross PPE | $304,150,000 | $296,426,000 | $331,650,000 | $273,151,000 |
| Leases | $63,812,000 | $63,039,000 | $66,579,000 | $63,103,000 |
| Other Properties | $106,227,000 | $103,795,000 | $139,411,000 | $94,102,000 |
| Machinery Furniture Equipment | $134,111,000 | $129,592,000 | $125,660,000 | $115,946,000 |
| Properties | $0 | $0 | $0 | $0 |
| Raw Materials | $63,625,000 | $39,572,000 | $48,998,000 | $46,956,000 |
| Other Short Term Investments | $2,295,000 | $2,201,000 | $65,184,000 | $302,433,000 |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $66,895,000 | $-253,643,000 | $-298,419,000 | $-327,961,000 |
| Operating Activities | ||||
| Operating Cash Flow | $83,155,000 | $-245,199,000 | $-276,100,000 | $-285,706,000 |
| Cash Flow From Continuing Operating Activities | $83,155,000 | $-245,199,000 | $-276,100,000 | $-285,706,000 |
| Operating Gains Losses | $19,895,000 | - | $10,915,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-16,260,000 | $-8,444,000 | $-22,319,000 | $-42,255,000 |
| Investing Cash Flow | $-16,260,000 | $52,932,000 | $214,774,000 | $-282,986,000 |
| Cash Flow From Continuing Investing Activities | $-16,260,000 | $52,932,000 | $214,774,000 | $-282,986,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-113,000 | $0 | $0 | - |
| Issuance Of Capital Stock | $649,697,000 | $0 | $0 | - |
| Financing Cash Flow | $664,989,000 | $200,292,000 | $10,132,000 | $10,445,000 |
| Cash Flow From Continuing Financing Activities | $664,989,000 | $200,292,000 | $10,132,000 | $10,445,000 |
| Net Other Financing Charges | $-30,261,000 | $-1,059,000 | $-2,300,000 | - |
| Net Preferred Stock Issuance | $121,238,000 | $0 | $0 | - |
| Preferred Stock Issuance | $121,238,000 | $0 | $0 | - |
| Net Common Stock Issuance | $528,346,000 | $0 | $0 | - |
| Common Stock Issuance | $528,459,000 | $0 | $0 | - |
| Other | ||||
| Repayment Of Debt | $-106,000 | $-157,000 | $-180,743,000 | $-962,000 |
| Issuance Of Debt | $27,865,000 | $199,978,000 | $191,310,000 | $0 |
| Interest Paid Supplemental Data | $43,520,000 | $49,017,000 | $15,776,000 | $24,240,000 |
| End Cash Position | $800,042,000 | $68,028,000 | $60,007,000 | $111,139,000 |
| Beginning Cash Position | $68,028,000 | $60,007,000 | $111,139,000 | $669,384,000 |
| Effect Of Exchange Rate Changes | $130,000 | $-4,000 | $62,000 | $2,000 |
| Changes In Cash | $731,884,000 | $8,025,000 | $-51,194,000 | $-558,247,000 |
| Proceeds From Stock Option Exercised | $17,907,000 | $1,530,000 | $1,865,000 | $11,407,000 |
| Common Stock Payments | $-113,000 | $0 | $0 | - |
| Net Issuance Payments Of Debt | $27,759,000 | $199,821,000 | $10,567,000 | $-962,000 |
| Net Long Term Debt Issuance | $27,759,000 | $199,821,000 | $10,567,000 | $-962,000 |
| Long Term Debt Payments | $-106,000 | $-157,000 | $-180,743,000 | $-962,000 |
| Long Term Debt Issuance | $27,865,000 | $199,978,000 | $191,310,000 | $0 |
| Net Investment Purchase And Sale | $0 | $61,376,000 | $237,093,000 | $-240,731,000 |
| Sale Of Investment | $0 | $61,376,000 | $300,488,000 | $137,645,000 |
| Purchase Of Investment | $0 | $0 | $-63,395,000 | $-378,376,000 |
| Net PPE Purchase And Sale | $-16,260,000 | $-8,444,000 | $-22,319,000 | $-42,255,000 |
| Purchase Of PPE | $-16,260,000 | $-8,444,000 | $-22,319,000 | $-42,255,000 |
| Change In Working Capital | $-33,127,000 | $-29,067,000 | $-7,129,000 | $-22,256,000 |
| Change In Other Current Assets | $48,000 | $121,000 | $-588,000 | $1,984,000 |
| Change In Payables And Accrued Expense | $22,514,000 | $577,000 | $8,431,000 | $2,312,000 |
| Change In Accrued Expense | $11,479,000 | $803,000 | $1,260,000 | $-6,598,000 |
| Change In Payable | $11,035,000 | $-226,000 | $7,171,000 | $8,910,000 |
| Change In Account Payable | $11,035,000 | $-226,000 | $7,171,000 | $8,910,000 |
| Change In Prepaid Assets | $-5,150,000 | $-1,408,000 | $4,544,000 | $-3,544,000 |
| Change In Inventory | $-20,750,000 | $5,459,000 | $-4,435,000 | $-11,103,000 |
| Change In Receivables | $-29,789,000 | $-33,816,000 | $-15,081,000 | $-11,905,000 |
| Changes In Account Receivables | $-29,789,000 | $-33,816,000 | $-15,081,000 | $-11,905,000 |
| Other Non Cash Items | $19,569,000 | $16,686,000 | $8,381,000 | $6,977,000 |
| Stock Based Compensation | $70,006,000 | $18,643,000 | $15,241,000 | $22,901,000 |
| Unrealized Gain Loss On Investment Securities | $52,285,000 | $-18,484,000 | $-11,094,000 | $-20,754,000 |
| Depreciation Amortization Depletion | $22,615,000 | $48,913,000 | $49,001,000 | $48,253,000 |
| Depreciation And Amortization | $22,615,000 | $48,913,000 | $49,001,000 | $48,253,000 |
| Net Income From Continuing Operations | $-68,088,000 | $-281,890,000 | $-341,415,000 | $-320,827,000 |
Fetched: 2026-06-17